Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reteplase - Chiesi Farmaceutici

Next Previous
Drug Profile

Reteplase - Chiesi Farmaceutici

Alternative Names: CUSA-081

Latest Information Update: 23 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Catheter thrombosis

Most Recent Events

  • 10 Jul 2023 Chiesi Farmaceutici terminates a phase III READY 1 trial for Catheter thrombosis in Argentina, Belgium, Poland, Romania, Spain, USA and Czech Republic (Intraluminal), due to recruitment challenges (NCT03594175) (EudraCT2019-002124-32)
  • 15 Apr 2022 Chiesi Farmaceutici withdraws a phase III trial in Catheter thrombosis in Bulgaria, Hungary and USA (Intraluminal), due to business decision (NCT03992443)
  • 22 Mar 2022 Reteplase is still in phase III trials for Catheter thrombosis in Argentina, Belgium, Poland, Romania, Spain, USA and Czech Republic (Intraluminal) (NCT03594175) (EudraCT2019-002124-32)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top